Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.
Company profile
Ticker
VALN, INRLF
Exchange
Website
CEO
Thomas Lingelbach
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VALN stock data
Latest filings (excl ownership)
6-K
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
26 Mar 24
20-F
2023 FY
Annual report (foreign)
22 Mar 24
6-K
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20 Mar 24
6-K
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18 Mar 24
6-K
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
4 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
15 Feb 24
6-K
Valneva Announces Sale of Priority Review Voucher for $103 Million
5 Feb 24
6-K
Current report (foreign)
10 Jan 24
6-K
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
8 Jan 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
31.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.11 bn |
Total shares | 21.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bpifrance Participations | 11.62 mm | $365.23 mm |
PFE Pfizer | 9.55 mm | $237.31 mm |
GAM General American Investors | 345.00 k | $5.06 bn |
Laurion Capital Management | 25.00 k | $367.00 mm |
MS Morgan Stanley | 3.36 k | $49.56 mm |
Advisor | 1.45 k | $21.69 mm |
Ridgewood Investments | 550.00 | $8.11 mm |
BCS Barclays | 170.00 | $3.00 k |
RY Royal Bank Of Canada | 20.00 | $0.00 |
Thrivent Trust Co of Tennessee | 6.00 | $0.00 |
News
Valneva Announces The Initiation Of Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
26 Mar 24
What Analysts Are Saying About Valneva Stock
22 Mar 24
Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17
22 Mar 24
Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M
20 Mar 24
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
19 Mar 24
Press releases
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26 Mar 24
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
25 Mar 24
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
21 Mar 24
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20 Mar 24
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18 Mar 24